Separable Features of the Ligand-Binding Domain Determine the Differential Subcellular Localization and Ligand-Binding Specificity of Glucocorticoid Receptor and Progesterone Receptor
Yihong Wan,
Kimberly K. Coxe,
Varykina G. Thackray,
Paul R. Housley and
Steven K. Nordeen
Department of Pathology and Program in Molecular Biology (Y.W.,
V.G.T., S.K.N.) University of Colorado Health Sciences Center
Denver, Colorado 80262
Department of Pharmacology and
Physiology (K.K.C., P.R.H.) University of South Carolina School of
Medicine Columbia, South Carolina 29208
 |
ABSTRACT
|
---|
Glucocorticoid receptor (GR) and progesterone
receptor (PR) are closely related members of the steroid receptor
family of transcription factors. The two receptors share a similar
domain structure, substantial sequence identity, DNA binding
specificity, and the ability to induce many of the same genes. Despite
these similarities, the unliganded GR is localized predominantly in the
cytoplasm, while unliganded PR is found predominantly in the nucleus.
By expressing green fluorescent protein (GFP)-tagged receptors and
assessing subcellular localization in living cells by confocal
microscopy, we have investigated the structural basis for the
differential localization of GR and PR. By constructing a
series of GFP-tagged receptor chimeras between GR and PR, we have shown
that multiple features in the N-terminal half of the ligand-binding
domain (LBD) are the critical determinants that mandate the
differential localization of GR and PR. Replacement of residues
encompassing helices 15 of GR with those of PR yields a receptor that
is nuclear. However, this domain is unable to mediate nuclear import by
itself when removed from the context of the receptor. The chimeric
receptors also indicate that regions encompassing helices 6 and 7 are
key determinants of the ligand binding potential and the
transactivation potential of receptors. Thus, the determinants
specifying localization of hormone-free receptors are separable from
those governing ligand binding character.
 |
INTRODUCTION
|
---|
The steroid hormones progesterone and cortisol have very distinct biological functions. The major physiological role of progesterone in the mammal is to establish and maintain pregnancy in the uterus and ovary, to promote lobular-alveolar development, and to suppress milk protein synthesis in the mammary gland during pregnancy (1). In contrast, classic actions of glucocorticoids include regulation of
glucose metabolism, inhibition of bone formation, and antiinflammatory
and immunosuppressive actions (2).
The receptors for progesterone (PR) and for glucocorticoids (GR) are
two closely related members of the nuclear receptor family of
transcription factors. They share very similar domain structures and
functional characteristics. Each N-terminal domain of the two
receptors, while nonhomologous, has ligand-independent
transcription activation function; the DNA-binding domain (DBD)
exhibits 86% sequence identity; the short hinge region has little
identity between receptors but is the location of a major nuclear
localization signal (NLS); and finally, the C-terminal
ligand-binding-domain (LBD) exhibits 54% identity between human (h) GR
and hPR, overlapping ligand-binding specificity, and a ligand-dependent
transcription activation function (3). The DBD and the LBD have been
characterized extensively both structurally and functionally. For both
receptors an optimal recognition site is an inverted hexameric
palindrome separated by 3 bp, PuGNACANNNTGTNCPy (4). In the absence of
hormone, receptor monomers form an inactive complex with molecular
chaperones, most notably heat shock protein 90 (hsp90) (5). Upon
binding of an agonist ligand to the receptor, it dissociates from
the chaperones and undergoes dimerization. The dimerized receptor binds
to recognition sites in target promoters and recruits coactivators,
resulting in increased transcription initiation at those promoters. In
a number of cases, both receptors can mediate induction of the same
genes (6, 7), although there are poorly understood influences of
chromatin that can differentially modulate induction by GR and PR (8).
How can two receptors with such remarkable similarities mediate such
dissimilar biological effects? The mechanism underlying the distinct
biological effects of glucocorticoids and progestins, even in cells
where both receptors are present, is a question of significant
interest.
Despite the remarkable similarities between these two receptors,
previous biochemical and immunochemical studies have shown that the
subcellular localization of GR vis a vis PR in the absence
of ligands is quite distinct. Although both receptors appear to
continuously shuttle, at any given moment GR is found largely in the
cytoplasm (912), while PR localizes to the nucleus (13). Hormone
binding results in tight association of the receptors with the nucleus.
The multipartite NLSs of GR and PR have been mapped in some detail
(1418). The major NLS is located just C-terminal to the DBD in the
hinge domain and is comprised of a stretch of clustered basic residues.
Two additional basic clusters in the second zinc finger of the DBD
contribute to the overall NLS activity. Interestingly, it has been
shown that the NLS in GR, which is cytoplasmic in the absence of
hormone, is just as potent as that of PR and ER, which are both
nuclear. A mutant PR, whose NLS has been replaced by the NLS of GR,
also localized to the nucleus in the absence of ligand (14). Thus,
current hypothesis posits that the differential localization of GR and
PR is not determined by the NLS but rather that the GR LBD can mask the
NLS. This view is based on the following observations: 1) LBD-truncated
GR is constitutively nuclear and has constitutive transcriptional
activity (1921); 2) when the LBD is moved to the N terminus of GR,
leaving the NLS at the C-terminal end of the receptor, the receptor is
constitutively nuclear (22); 3) an antibody (AP64) against the major
NLS can react with liganded GR but not unliganded receptor (23). It is
unclear whether the LBD itself or the hsp90 bound to the LBD masks the
NLS, although some evidence favors hsp90 (24). However, the hypothesis
that the LBD or associated proteins masks the NLS has been challenged
(25, 26).
In this study, we seek to define the receptor domain that determines
the differential localization between GR and PR. We use receptors
tagged with green fluorescent protein (GFP) to monitor the subcellular
localization of steroid receptors by confocal microscopy. GFP from
the jellyfish, Aequorea victoria, has been developed into an
extremely useful tool to monitor protein localization and trafficking.
Many proteins, when fused to GFP, maintain their normal function and
localization (27). The utility of GFP has been extended by the
selection of enhanced variants that exhibit increased fluorescence; in
addition, codon usage has been humanized to improve translation.
Fluorescence can be monitored in living cells, thereby avoiding
artifacts caused by biochemical fractionation or fixation. GFP is
proving to be an extremely useful means of dissecting the localization
of nuclear receptors and the dynamics of receptor trafficking (26,
2831). Here, we use GFP-tagged receptors to monitor the differential
subcellular localization between GR and PR. By assessing a series of
GFP-tagged receptor chimeras, we show that it is the LBD that
determines the differential localization of the two highly related
receptors. Chimeras between the two LBDs implicate multiple features
within the N-terminal half of the LBD in the specification of the
nuclear or cytoplasmic localization of the receptor in the absence of
hormone. However, the context of this region within the receptor is
critical since it cannot by itself promote nuclear import or export.
Mutagenesis studies of steroid receptors along with ligand-LBD crystal
structures from different members of the nuclear receptor family,
including PR (32, 33), implicate residues in the N-terminal portion of
the LBD in ligand binding specificity. Nonetheless, we show that there
is not a strict correlation between the ligand binding specificity of
the receptor, its subcellular localization, or capacity for
transactivation, implying that distinct structural features determine
these properties.
 |
RESULTS
|
---|
GFP-GR and GFP-PR Can Be Used to Monitor Receptor Localization and
Are Biologically Active
To examine whether GFP-GR and GFP-PR exhibited a subcellular
localization like that of wild-type GR and PR, expression vectors
encoding GFP-GR and GFP-PR fusion proteins were transiently transfected
into COS-1 cells, Ltk-, or E82.A3 fibroblasts.
Multiple cell lines were employed to assess consistency of results.
COS-1 cells have features that optimize visualization, including
excellent adherence, a flat morphology, and high levels of protein
expression caused by vector replication. E82.A3 is a clonal cell line
derived from mouse L cells that has been selected for the absence of
endogenous GR expression (34). In addition, these cells do not express
PR. The level of receptor expression in transfected E82.A3 cells is
lower than in COS-1 cells. Ltk- cells display
fibroblast morphology and transfect well, but express low levels of
endogenous GR.
Receptor localization was assessed by confocal microscopy in living
cells. Similar results were seen in all three lines, and confocal data
for COS-1 and E82.A3 cells are shown in Fig. 1
. GFP itself is distributed throughout
the cell; this distribution is unaffected by hormones. GFP-GR is found
predominantly in the cytoplasm in the absence of hormone. Treatment of
GFP-GR-expressing cells with dexamethasone is accompanied by the rapid
movement of receptor to the nucleus (t1/2
5
min). Nuclear receptor remains excluded from nucleoli. In contrast,
GFP-PR localizes predominantly to the nucleus in the absence of
hormone, although cytoplasmic GFP-PR is sometimes seen, especially when
the receptor is overexpressed. GFP-PR remains nuclear after hormone
addition as expected.

View larger version (36K):
[in this window]
[in a new window]
|
Figure 1. Subcellular Localization of GFP-Tagged Receptors
COS-1 cells and E82.A3 cells were transfected with the indicated
expression vectors. Hormone treatment of transfected cells with
vehicle, dexamethasone (100 nM), or R5020 (20
nM) was for 1 h. Cells transfected with GFP-vector and
GFP-GR were treated with dexamethasone; cells transfected with GFP-PR
were treated with R5020. Confocal microscopy was conducted on live,
unfixed cells.
|
|
Reporter gene transfection experiments indicate that GFP-GR and GFP-PR
fusion proteins retain biological activity. The GFP-tagged receptors
mediate the induction of a hormone-responsive mouse mammary tumor virus
(MMTV)-luciferase reporter as effectively as wild-type GR and PR (Fig. 2C
). These results demonstrate that the
GFP-GR and GFP-PR chimeras recapitulate the cellular distribution
expected of GR and PR as well as the wild-type transcriptional
activity.

View larger version (48K):
[in this window]
[in a new window]
|
Figure 2. The LBD Determines Subcellular Localization of
Chimeric Receptors
A, Schematics of chimeric receptors in which the LBD of GFP-GR and
GFP-PR-B have been exchanged. B, Subcellular localization of GFP-tagged
chimeric receptors. Cells transfected with P/G were treated with
dexamethasone (100 nM); cells transfected with G/P were
treated with R5020 (20 nM). Confocal microscopy was
conducted on live, unfixed cells. C, The function of GFP-tagged
receptors and receptor chimeras was assessed by cotransfection of 1
µg/ml of the indicated receptor expression vector with a reporter
plasmid pAHLuc into E82.A3 cells. Reporter gene expression was assessed
2024 h after the addition of 100 nM dexamethasone (Dex),
20 nM R5020, or vehicle (Veh) to the transfected cells.
Luciferase activity has been normalized to the expression of
ß-galactosidase directed by the internal transfection control plasmid
pCMVß-gal. hGR-I9 represents a fully functional receptor with a small
insertion at amino acid 9. I9 was used in the construction of all
GFP-hGR (see Materials and Methods). The higher activity
of GFP-hGR vs. hGR-I9 is likely due to the higher
expression of the receptor from the strong CMV promoter on the GFP
expression vector. The figure depicts the results of three independent
experiments within which each condition was done in duplicate.
Bars represent ± SE.
|
|
Differential Localization of GR and PR Is Determined by the
Ligand-Binding Domain
To determine which functional domain of GR and PR is responsible
for the differential localization of the unliganded receptors,
expression vectors encoding GFP-tagged receptor chimeras were
constructed (Fig. 2A
). The presence of a unique BclI site
adjacent to the hinge-LBD border of hPR (35) facilitates the
construction of GFP-tagged receptors in which the LBDs of PR and GR are
exchanged. Thus, G/P contains the entire N terminus, DBD, and hinge
from hGR and the entire LBD from hPR with GFP at the N terminus of the
chimeric receptor. Conversely, P/G is the complement where only the LBD
is derived from GR. Unliganded G/P is nuclear in both COS-1 cells and
E82.A3 cells, whereas unliganded P/G is cytoplasmic, redistributing to
the nucleus on dexamethasone addition (Fig. 2B
). Thus, while the
multipartite NLS is necessary for nuclear import of both GR and PR
(14, 15, 16, 17, 18), it is the LBD that determines the differential localization
of the unliganded receptor. The chimeric receptors retained
transcriptional activity. P/G was fully activated by the synthetic
glucocorticoid dexamethasone and G/P by the synthetic progestin R5020
(Fig. 2C
).
Nuclear Localization Specificity Maps to the N-Terminal Half of the
LBD but Is Separable from Ligand Binding Specificity
To localize further the region within the LBD that is responsible
for the differential localization of GR and PR, additional chimeras
within the LBD were created. Portions of the PR LBD were replaced by
the homologous portions of GR, taking advantage of three natural
restriction sites in PR that divide the LBD into four segments (see
Fig. 3A
and Materials and
Methods). Thus, in the expression vectors
P/P1-9G1
and P/P1-7G, C-terminal PR sequences have been
replaced with 82 or 123 amino acids of GR sequence, respectively. When
expressed in cells, both receptors were nuclear without ligand (Fig. 3B
), like PR itself, indicating that the C-terminal half of the
LBD has little role in differential receptor localization.
Furthermore, since P/P1-7G
differs from the P/G only in the origin of the N-terminal half of the
LBD yet exhibits nuclear rather than cytoplasmic localization, it
suggests that sequences encompassed by the 123 amino acids of the
helices 17 segment determine differential localization of GR and PR.
The construction and analysis of additional vectors confirmed this
suggestion. G/P1-9G and
G/P1-7G were nuclear in
the absence of ligand just as
P/P1-9G and
P/P1-7G (Fig. 3
),
confirming that sequences N-terminal to the LBD are not involved in the
differential localization of GR and PR.

View larger version (47K):
[in this window]
[in a new window]
|
Figure 3. Nuclear Localization Specificity Maps to the
N-Terminal Half of the LBD but Is Separable from Ligand Binding
Specificity
A, Schematics of receptors with chimeric LBDs. The GFP tag at the N
terminus of the receptors is not depicted. The distribution of the
receptor after transient expression in COS-1 and E82.A3 cells is
indicated to the right of the schematic. Treatment with
vehicle (Veh), dexamethasone (Dex, 100 nM), or R5020 (20
nM) was for 1 h. The BclI site present
at the boundary of the hinge region and the LBD is represented as a
solid vertical line. aa, Amino acid. "N" indicates
that most or all cells have a distribution that is entirely nuclear or
nuclear>>cytoplasmic. "C" indicates that most or all cells have a
distribution that is entirely cytoplasmic or cytoplasmic>>nuclear.
"N+C" indicates that most or all cells have an approximately equal
nuclear and cytoplasmic distribution of fluorescence. B, Representative
confocal images of transfected COS-1 cells expressing the chimeric
receptors shown in panel A and treated with hormone or vehicle as
indicated.
|
|
Unlike G/P1-7G, the
chimera G/P1-3G was
cytoplasmic (Fig. 3
), indicating that sequences within the helices 47
segment play a role in specifying localization. However, helices 47
are insufficient to specify localization, because the chimera
P/GP4-12, the converse of
G/P1-3G, is, like
G/P1-3G, also cytoplasmic
in the absence of hormone (Fig. 3
). If an LBD chimera and its converse
both exhibit a similar localization pattern, one of two possibilities
exists: either both chimeras exhibit the default localization phenotype
because the localization signal has been disrupted or, conversely, both
chimeras exhibit a directed localization because the signal has
multiple components that can each act independently. Thus, the finding
that the converse pair,
P/GP4-12 and
G/P1-3G, are both
cytoplasmic could signify that this is the default localization,
suggesting that in the chimeras an NLS present in PR has been
disrupted. This could be either a single, contiguous determinant or a
multipartite signal. Alternatively, nuclear localization is the default
and determinants from both the GR helices 47 and GR helices 13
regions can independently specify cytoplasmic localization,
e.g. by serving as nuclear export signals. We believe this
latter alternative to be less likely, in part because placing an NLS at
the N terminus of GR creates a constitutively nuclear receptor (Ref. 22
and L. Taraseviciene and S. K. Nordeen, unpublished results).
Additional results below address these possibilities and further
localize the determinants.
Chimera G/P1-3G
redistributes to the nucleus upon addition of the glucocorticoid
dexamethasone. In contrast,
P/GP4-12 does not.
However, P/GP4-12 can bind
the progestin R5020, albeit poorly, since it only partially
redistributes to the nucleus after exposure to ligand. Since
P/GP4-12 binds progestins
in preference to glucocorticoids yet is cytoplasmic in the absence of
ligand, it suggests that localization and hormone binding specificity
are separable properties of receptors. Additional chimeras confirm this
suggestion as detailed below.
Multiple Subdomains of the LBD Contribute to Localization
The next series of chimeras were constructed to determine which
domains within the N-terminal half of the LBD are involved in receptor
localization (Fig. 4A
).
P/P1-speG is a chimera in which the fusion was
made at an introduced SpeI site within the third helix. The
converse chimera is
G/GPspe-12 in which the
only LBD sequences from GR are the first helix, spacer, and the first 4
amino acids of the third helix. When expressed in cells, both of these
chimeric receptors are cytoplasmic like GR (Fig. 4B
). The fusion of PR
and GR sequences at the introduced SpeI site within helix 3
may have disrupted an NLS. To test this, the four GR residues of the
third helix of G/GPspe-12
LBD (WRIM) were mutated to PR sequence (SSLL) to create
G/GP3-12 where the entire
helix 3 to C-terminal sequence is from PR. In the absence of ligand,
this chimera is still largely cytoplasmic. This suggests that PR LBD
sequence N-terminal to helix 3, along with the helices 47 domain
implicated above, contribute to the specification of a PR-like nuclear
localization.

View larger version (54K):
[in this window]
[in a new window]
|
Figure 4. Multiple Subdomains of the N-Terminal Portion of
the LBD Contribute to Localization
A, Schematics of receptors with chimeric LBDs. The GFP-tag at the N
terminus of the receptors is not depicted. The distribution of the
receptor after transient expression in COS-1 and E82.A3 cells is
indicated to the right of the schematic. Treatment with
vehicle (Veh), dexamethasone (Dex, 100 nM), or R5020 (20
nM) was for 1 h. "H3" stands for helix 3; aa,
amino acid. "N" indicates that most or all cells have a
distribution that is entirely nuclear or nuclear>>cytoplasmic. "C"
indicates that most or all cells have a distribution that is entirely
cytoplasmic or cytoplasmic>>nuclear. B, Representative confocal images
of transfected COS-1 cells expressing the chimeric receptors shown in
panel A and treated with hormone or vehicle as indicated.
|
|
While both P/P1-speG and the converse chimera,
G/GPspe-12, are
cytoplasmic in the absence of ligand, they exhibit distinct ligand
specificities. Dexamethasone drives nuclear redistribution of the
former while the latter redistributes in response to progestins. Like
G/GPspe-12,
G/GP3-12 also
redistributes completely to the nucleus upon addition of R5020.
Together these results indicate that although LBD sequences
N-terminal to helix 3 are involved in subcellular localization of
the ligand-free receptor, they do not play a significant role in
the specification of ligand recognition.
Results presented above (Fig. 3
) demonstrated that
G/P1-3G is cytoplasmic and
that G/P1-7G is nuclear.
The next series of constructs attempted to refine the requirement for
PR sequences from helices 4 through 7 in nuclear localization. Some of
the greatest sequence disparity between the LBD of GR and PR occurs in
helix 7. Furthermore, sequences in helix 7, helix 6, and the ß-turn
structure preceding helix 6 have been implicated in differential ligand
recognition (36). We therefore constructed chimeras based on
G/P1-3G and
G/P1-speG replacing GR sequence with PR helix 7
or a larger PR block encompassing the ß-turn, helix 6, and helix 7
(Fig. 5
, A and B). All of the
resulting double chimeras,
G/P1-3GP7G,
G/P1-3GP6-7G,
G/P1-speGP7G, and
G/P1-speGP6-7G,
retained a cytoplasmic phenotype in the absence of ligand (Fig. 5C
),
indicating a role for PR sequences in helix 4 and/or helix 5 in the
acquisition of a nuclear phenotype. The double LBD chimeras all had
altered ligand recognition specificity compared with the progenitors,
G/P1-3G and
G/P1-speG. All double chimeras could translocate
to the nucleus in response to R5020, and all exhibited a reduced
ability of dexamethasone to induce translocation (Fig. 5C
).


View larger version (149K):
[in this window]
[in a new window]
|
Figure 5. Helices 15 of the LBD Determine Steroid Receptor
Localization
A, Schematics of receptors with chimeric LBDs. The GFP tag at the N
terminus of the receptors is not depicted. The distribution of the
receptor after transient expression in COS-1 and E82.A3 cells is
indicated to the right of the schematic. Treatment with
vehicle (Veh), dexamethasone (Dex, 100 nM), or R5020 (20
nM) was for 1 h. aa, Amino acid. "N" indicates
that most or all cells have a distribution that is entirely nuclear or
nuclear>>cytoplasmic. "C" indicates that most or all cells have a
distribution that is entirely cytoplasmic or cytoplasmic>>nuclear.
"N>C" indicates that most or all cells have a distribution that is
nuclear>cytoplasmic but there is a significant level of cytoplasmic
distribution B, Amino acid sequences of the helices 17 region of hGR,
hPR, and the double chimeras shown in panel A. hPR sequences are in
bold and underlined. Amino acids included in each helix
or the ß-turn region are indicated by an overline. The
location of each restriction site used in receptor chimera construction
is indicated by an arrow. C, Representative confocal
images of transfected COS-1 cells expressing the chimeric receptors
shown in panel A and treated with hormone or vehicle as indicated. Fig. 5C can be found on the facing page.
|
|
The final chimera that was examined was
G/P1-5G in which the first
87 amino acids (through helix 5) of the LBD are derived from PR (Fig. 5
, A and B). It exhibits largely nuclear localization in the absence of
ligand (Fig. 5C
). This chimera represented the receptor with the
smallest region of PR that retained a predominantly nuclear phenotype
in the absence of ligand. This chimera binds glucocorticoids, as
evidenced by the fact that the remaining cytoplasmic receptor could be
driven to the nucleus upon addition of dexamethasone and is
transcriptionally active in response to dexamethasone (see below).
Thus, several different chimeras demonstrated that a receptor
binding a glucocorticoid ligand could be nuclear in the absence of
ligand and, conversely, that a progestin binding receptor could be
cytoplasmic in the ligand-free state. Therefore, the structural
features that determine localization in the ligand-free state and those
that determine ligand specificity are distinct and separable.
The Sequences That Specify Nuclear Localization Do Not Act as an
Independent NLS
To test whether a region of PR that can specify nuclear
localization contains an independent NLS, the 123-amino acid domain
encompassing helices 17 was fused to a dimer of GFP (Fig. 6A
). A GFP dimer has a molecular
mass of about 54 kDa and is distributed mostly in cytoplasm
(C>N). When expressed in COS cells, the fusion protein
(GFP)2-PR1-7
is predominantly cytoplasmic (Fig. 6B
). This result indicates that the
helices 17 domain does not itself serve as an independent NLS.
However, this conclusion must be tempered by the uncertainty that
helices 17 can fold properly in the absence of the rest of the
LBD.

View larger version (16K):
[in this window]
[in a new window]
|
Figure 6. The Sequences That Specify Nuclear Localization Do
Not Act as an Independent NLS
A, Schematics of GFP fusion proteins. B, Representative confocal images
of transfected COS-1 cells expressing the chimeric proteins shown in
panel A.
|
|
Ligand Binding and Transactivation Properties of Receptors with
Chimeric LBDs
To ensure that LBD chimeras were, in fact, active receptors and,
therefore, that localization results were not in some way artifactual,
many of the chimeras were assessed for their capacity to be activated
by a specific glucocorticoid, dexamethasone, and a specific progestin,
R5020. Receptor expression vectors were transiently transfected into
E82.A3 cells together with an MMTV-luciferase reporter plasmid and a
cytomegalovirus (CMV)-ß galactosidase internal control plasmid.
Many of the chimeras can transactivate gene expression in response to
the appropriate steroid (Fig. 7A
). In
parallel, direct ligand binding assays were performed to examine the
suppositions made with regard to ligand specificity based on
ligand-mediated receptor redistribution. Ligand binding was assessed by
whole-cell binding assays after transient expression of receptors in
COS-1 cells (Fig. 7B
). These studies confirm that the structural
features governing ligand binding and activation capacity of a receptor
are not coincident with those that determine its distribution in the
absence of hormone. Also, as detailed below, a number of
inferences can be made concerning the role of different domains in
ligand specificity and transactivation.

View larger version (32K):
[in this window]
[in a new window]
|
Figure 7. Transactivation and Ligand Binding Properties of
Receptors with Chimeric LBDs
A, Transactivation by chimeric receptors. Each indicated receptor
expression vector was transfected into E82.A3 cells and cotransfected
with a reporter plasmid pAHLuc and an internal control plasmid
pCMVß-gal as described in Materials and Methods.
Induction of luciferase was assessed after a 24-h exposure to
dexamethasone (Dex, 1 µM), R5020 (1 µM), or
vehicle (Veh). Luciferase activity has been normalized to the
expression of ß-galactosidase. The figure depicts the results of two
independent experiments within which each condition was done in
duplicate. Bars represent ± range. B, Whole-cell
ligand binding assays. COS-1 cells were transiently transfected to
express the indicated receptor chimeras. Specific hormone binding for
dexamethasone (Dex, 20 nM) and R5020 (1 nM) are
shown as a percentage of that seen with GFP-GR or GFP-PR, respectively.
The figure depicts the results of two independent experiments where
each condition was done in triplicate. Bars
represent ± range.
|
|
The nuclear chimeric receptor,
G/P1-7G, in which the
C-terminal 123 amino acids of PR sequence have been replaced by
the homologous GR sequence, still binds and is activated by R5020.
Although this receptor exhibits some glucocorticoid binding (
20% of
wild type), it is only minimally activated even at very high levels of
dexamethasone. Replacement with additional GR sequence,
G/P1-5G, still results in
a receptor with a largely nuclear distribution. However, this chimeric
receptor now exhibits a strong preference for binding to and activation
by glucocorticoids. These data concur with the implications of the
ligand-mediated redistribution data that the ß-turn helices 67
region possesses key determinants for steroid binding specificity.
Additional chimeras confirm the key role of this region. Chimera
G/P1-3G binds
glucocorticoids similarly to GR and is transcriptionally activated by
dexamethasone. When the ß-turn-helix 6-helix 7 region is changed to
PR sequence
(G/P1-3GP6-7G),
the resulting double chimera does not bind to glucocorticoids nor
respond to them. Instead, this chimera displays significant binding to
R5020 (albeit reduced from wild-type PR) and a proportionate
transactivation response. When only helix 7 instead of the
ß-turn-helix 6-helix 7 region is changed to PR sequence in another
double chimera,
G/P1-3GP7G,
the receptors can still relocalize in response to high levels of R5020
although neither R5020 nor dexamethasone binding or transactivation is
observed. The observation that this double chimeric receptor can
redistribute to the nucleus in response to ligand but fail to
transactivate will be addressed in the Discussion.
Along with the ß-turn-helices 67 region, helix 3, which forms part
of the ligand binding pocket (32, 33), contributes to ligand
binding and specificity.
G/GP3-12 binds well to
progestins and undetectably to glucocorticoids. Replacing helix 3 with
the homologous GR sequence
(P/GP4-12) abrogates R5020
binding. Even changing only four amino acids at the N terminus of helix
3 to make G/GPspe-12
reduces R5020 binding 4-fold compared with
G/GP3-12. Thus, together
these chimeras indicate that the best R5020 binding is seen when the
entire helix 3 through helix 7 region is derived from PR.
Interestingly, the origin of helix 3 is of lesser consequence to
glucocorticoid binding. For example,
G/P1-3G binds
dexamethasone well. However, now changing the helices 67 domain to PR
sequence
(G/P1-3GP6-7G)
abrogates glucocorticoid binding. This binding can be partially
recovered by changing part of helix 3 to GR sequence
(G/P1-speGP6-7G)
as can a proportionate degree of transactivation. Thus, while the helix
3 sequences may be less important in glucocorticoid specificity than
progestin specificity, they do contribute in the context of additional
domains of the LBD. Together, these data indicate that sequences
governing ligand specificity overlap, but are not coincident with, the
functional domains that govern differential localization of the two
receptors.
 |
DISCUSSION
|
---|
As a matter of convenience, throughout this manuscript, we have
referred to the subcellular distribution of GR and PR at a given moment
as localization. By no means is this intended to imply that the
distribution of these receptors is static. Indeed, the current
understanding is one of exquisite dynamism as recent results from
several laboratories indicate. Both in the presence and absence of
ligand, GR and PR shuttle continuously between nucleus and cytoplasm
(25, 37, 38). Thus, the equilibrium distribution at any moment
represents the net of the nuclear import and export steps. The
mechanisms and mediators of these steps are not well understood for
steroid receptors. One recent report suggests both the nuclear import
and export of rabbit PR can be competed by the SV-40 NLS coupled to
BSA. Several lines of evidence also indicate that export of PR does not
occur through an NES-CRM-1-mediated pathway (37). Results with rat GR
have implicated NES-CRM-1 in nuclear export (26) although more recent
work does not support the involvement of this pathway in GR trafficking
(39).
Among the steroid receptors, there is general agreement that
hormone-free PR and the estrogen receptor are nuclear (13, 40). Recent
studies employed GFP-tagged receptors to compare the localization of
the two isoforms of PR (31). In this work, the distribution of the two
isoforms differed somewhat, with GFP-PR-B on average showing slightly
more nuclear than cytoplasmic fluorescence and GFP-PR-A predominantly
nuclear staining. We also find some GFP-PR-B transfected cells with
detectable cytoplasmic fluorescence, although most of the cells exhibit
predominantly or entirely nuclear fluorescence. In contrast to PR, GR
and the mineralocorticoid receptor are cytoplasmic (9, 10, 11, 12, 41, 42).
Both nuclear and cytoplasmic localization of the androgen receptor have
been reported (43, 44, 45, 46, 47). In this work we have mapped the sequence
domains of GR and PR that control the differential distribution of
the two receptors in a ligand-free state. Although the sequences of
the GR and PR that render the receptor capable of nuclear localization
upon hormone addition have been mapped to two clusters of basic amino
acids in the DBD and another in the hinge (14, 15, 16, 17, 18), previous work in
which the LBD of the PR was replaced with that of GR implicated the LBD
in determining the differential distribution of the two receptors in
the absence of hormone (14). We have extended this work using receptor
chimeras to delineate the sequences that control the differential
distribution. Our approach has employed an enhanced GFP tag to follow
the receptor in contrast to most previous studies on receptor
localization and trafficking that have used indirect
immunofluorescence. A green fluorescent protein tag permits the
visualization of receptor proteins in living, unfixed cells and
therefore represents a valuable alternative approach to studies on
receptor trafficking. In addition, due to the similarity of the LBDs of
GR and PR, receptor chimeras used in our study maintain the receptor
integrity and overall conformation compared with receptor deletion
mutants, as evidenced by the ability to bind hormone and, in most
cases, to transactivate in response. This is not unexpected. The
crystal structure of the LBD of hPR bound to progesterone has been
solved to a 1.8 Å resolution (32, 33). Despite amino acid identity as
low as 15%, PR exhibits an overall structure very similar to other
members of the nuclear receptor family for whom the crystal structure
is available.
Notwithstanding the overall conformational similarity and extensive
sequence identity of the LBD, GR and PR exhibit distinct ligand binding
properties and distinct subcellular distribution patterns in the
ligand-free state. The examination of many chimeric LBDs has shown that
determinants of ligand binding specificity and differential
localization are separable. The region of helices 15 determines
subcellular localization specificity, while helix 7 and the larger
ß-turn-helix 6-helix 7 domain along with helix 3 make important
contributions to ligand recognition. Therefore, a glucocorticoid
binding chimeric receptor could be nuclear, and conversely a progestin
binding chimeric receptor could be cytoplasmic in the ligand-free
state.
Interestingly, a subset of chimeras (the double chimeras, Figs. 5
and 7
) could redistribute from cytoplasm to nucleus upon addition of
ligand, yet they exhibited greatly reduced or ablated transactivation
capability. GR is driven to the nucleus by ligand relatively quickly
(t1/2 5 min) yet GR that has been withdrawn from
hormone redistributes into the cytoplasm only slowly
(t1/2 4 h) even though nucleocytoplasmic
shuttling continues and reestablishment of an 8S complex has occurred
(25, 48). In light of these kinetics, it stands to reason that the
addition of hormone to a chimeric receptor whose structure reduces
hormone affinity because of a high off rate may cause some nuclear
accumulation even though the receptors are only occupied a small
fraction of the time. The chimeric receptor may not be able to assume a
proper conformation to bind coactivators and thus fail to promote
transactivation. Alternatively, a high ligand off rate may not
allow sufficient time for the completion of the full set of
receptor-promoted steps necessary to initiate a round of transcription
initiation before the entire process is aborted by ligand
dissociation.
The examination of the GFP-tagged receptor chimeras has
narrowed the domain that determines the differential distribution of
unoccupied GR and PR to the N-terminal 87 amino acids of the LBD
(helices 15) and suggest that multiple determinants may be involved
in specifying nuclear localization. This region of GR and/or PR has
been implicated in binding of chaperone proteins and in ligand binding.
The present work implies that this region may have yet another role in
interacting with nuclear trafficking proteins to determine kinetics of
the import and export steps and therefore the equilibrium distribution
of the protein. The difference in nucleocytoplasmic trafficking between
ligand-free GR and PR suggests that the helices 15 region of the GR
LBD may have a distinct conformation compared with PR. As mentioned
earlier, GR that has been withdrawn from hormone redistributes into the
cytoplasm only slowly even though nucleocytoplasmic shuttling continues
and reestablishment of an 8S complex has occurred (25, 48). It may be
that this hormone-withdrawn state represents an LBD conformation that
is more PR-like and that reverts slowly to a conformation that is more
typical of the naive receptor. Binding of the antiprogestin RU486 to GR
appears to entrain a conformation that favors nuclear localization as
GR withdrawn from RU486 fails to redistribute to the cytoplasm (Refs.
25, 48 and P. R. Housley, unpublished). Data with RU486 and
with the pure antiestrogen ICI182 780 (49) suggest that disruption of
the normal nucleocytoplasmic trafficking of receptors may play a role
in the mechanism of action of steroid antagonists. The widespread
clinical use of steroid antagonists makes this an important question to
understand more fully.
The functional consequences of the differential localization
of PR and GR are not clear. However, there are indications that the
localization of PR may be regulated in a developmental or
tissue-specific fashion (50). This regulation suggests that there are
indeed biological consequences of receptor localization. Preliminary
findings that suggest a molecular target have come from yeast
two-hybrid studies. These studies indicate that PR has a strong SH3
binding domain and can physically interact in vitro with
cell signaling molecules, such as the tyrosine kinase src, and regulate
activity (51). Since these cell-signaling molecules are present
predominantly in compartments other than the nucleus, such findings
highlight the importance of a thorough understanding of steroid
receptor trafficking.
 |
MATERIALS AND METHODS
|
---|
Plasmid Construction
GFP-hGR
was constructed by cloning a
BamHI-XhoI fragment from pI9 (52) into the GFP-C2
vector (CLONTECH Laboratories, Inc., Palo Alto, CA).
GFP-hPR was constructed by cloning an EcoRI-ScaI
fragment from hPR1 (35) into the GFP-C1 vector (CLONTECH Laboratories, Inc.). Receptor chimeras G/P, P/G,
P/P1-9G,
P/P1-7G,
G/P1-3G, and
P/GP4-12 were constructed
by cloning fragments of hGR amplified by PCR using Pfu polymerase
(Stratagene, La Jolla, CA). Appropriate restriction sites
were incorporated into the primers to facilitate the in-frame junction
with naturally occurring restriction sites within hPR (see Fig. 3A
).
The BstBI site in the PR LBD immediately follows the coding
region encompassing LBD helix 3, HindIII follows helix 7,
and Ecl136 II cuts near the C terminus of helix 9. All PCR-generated
sequences were confirmed by sequencing. Receptor chimeras
G/P1-9G and
G/P1-7G were constructed
by replacing the LBD in G/P with the chimeric LBD from
P/P1-9G and
P/P1-7G, respectively,
utilizing the BclI site at the junction between the hinge
and the LBD. SpeI sites were introduced into the LBD of
GFP-GR
and GFP-PR-B by Quick-Change site-directed mutagenesis
(Stratagene), and the products were confirmed by DNA
sequencing. Receptor chimeras P/P1-speG and
G/GPspe-12 were
constructed by using these SpeI sites. Chimera
G/P1-speG was constructed by replacing the LBD in
G/P with the LBD fragment from P/P1-speG at
the BclI site. Chimera
G/GP3-12 was constructed
from G/GPspe-12 by
Quick-Change site-directed mutagenesis (Stratagene),
changing the sequences encoding the four amino acids immediately
N-terminal of the introduced SpeI site from GR-like (WRIM)
to PR-like (SSLL). The changes were confirmed by DNA sequencing. All
the double chimeric receptors were constructed using the gene Splicing
by Overlapping Extension (SOE) procedure (53, 54).
G/P1-3GP6-7G
and
G/P1-3GP7G
were constructed using
G/P1-3G and
G/P1-7G as progenitors.
G/P1-speGP6-7G
and G/P1-speGP7G were
constructed using G/P1-speG and
G/P1-7G as progenitors.
G/P1-5G was constructed
using G/P1-7G and GFP-GR
as progenitors. Additional details on plasmid constructions,
including the oligonucleotides used for PCR and for site-directed
mutagenesis, are available on request.
Cell Culture and Transfection
Mouse fibroblast E82.A3 and Ltk- cells
were maintained in MEM (Life Technologies, Inc.,
Gaithersburg, MD) supplemented with 5% FBS (HyClone Laboratories, Inc.), 10 mM HEPES, and nonessential
amino acids. Transient transfections of both lines were performed using
a diethylaminoethyl (DEAE)/Dextran method as previously described (55).
For fluorescence experiments, cells were plated on coverslips in
culture dishes and transfected with 5 µg/ml of receptor expression
vector. Cells were maintained in medium containing charcoal-stripped
serum before fluorescence imaging. Fluorescence was assessed 2430 h
after transfection and 1 h after vehicle or hormone addition. For
quantitation of reporter gene expression, cells were transfected with 1
µg/ml of receptor expression vector. Cells were cotransfected with 2
µg/ml of pAHluc and 0.1 µg/ml of pCMVß-gal. The response of the
former was used to assess hormone response, and the latter served as an
internal transfection control. The promoter of pAHluc is an
AvaI-HpaII fragment spanning nearly the entire
MMTV long terminal repeat. Cells were treated with hormone for 2024 h
beginning the second day after transfection. Extracts were prepared by
first washing the cells, harvesting them in 0.5 ml of cell lysis
buffer, and then pelleting debris (55). For luciferase assays, 25 µl
of soluble lysate were used and for ß-galactosidase assays, 2.5 µl
were used. Luciferase and ß-galactosidase assays were assessed using
a Monolight 3010 luminometer (Analytical Luminescence Laboratory, San Diego, CA) as previously described (55). Data
are reported as luciferase activity normalized to
ß-galactosidase activity in the same transfection.
COS-1 cells were maintained in DMEM (Life Technologies, Inc.) supplemented with 10% FBS (Life Technologies, Inc.). Transient transfection of COS cells was performed using a
modified DEAE/Dextran method with 200 µg/ml DEAE/Dextran and 30
µM chloroquine. Cells were incubated in the
DNA-DEAE/Dextran-chloroquine transfection mixture for 2 h at 37 C.
The transfection mixture was aspirated and the cells subjected to a
1-min shock (55). Cells were then washed twice with PBS and refed with
DMEM with charcoal-stripped serum. Hormone or vehicle were added 1820
h after transfection and fluorescence was monitored 1 h
thereafter.
Fluorescence Microscopy
Transfected cells on coverslips were analyzed by confocal
scanning laser microscopy with a MRC instrument (Bio-Rad Laboratories, Inc., Hercules, CA). Living cells in medium were
scanned at low laser power to avoid photobleaching and at a sufficient
depth to correctly assess the presence of intranuclear signal. The
figures show representative cells from each transfected DNA; at least
50100 cells from each transfection were inspected and scored as
described in the legend to Fig. 3
.
Whole-Cell Hormone Binding Assays
For hormone binding assays, 5 µg/ml of each construct was
transfected as described into COS-1 cells in six-well plates (R5020
assays) or a T150 flask (dexamethasone assay). For the latter, cells
were replated into six-well dishes 24 h after transfection so that
they would be 6070% confluent at the time of harvest. Forty eight
hours after transfection, three wells were treated with
3H-labeled hormone for total hormone binding,
three wells were treated with 3H-labeled hormone
plus excess unlabeled hormone for nonspecific binding, and three wells
were left untreated for protein determination. For R5020 binding assay,
cells were treated with 1 nM
3H-R5020 ± 100 nM unlabeled
R5020. For dexamethasone binding assay, cells were treated with 20
nM 3H-dexamethasone ± 20
µM unlabeled dexamethasone. After incubation for 4 h
at 37 C, the cells were washed five times with cold PBS. Hormone was
then extracted with ethanol at room temperature for 30 min. Ethanol was
transferred into scintillation vials for quantitation of bound hormone.
To obtain specific binding (picomoles/mg protein) the following formula
was used: total binding - nonspecific binding - specific
binding from empty vector transfected cells. The latter term is
included to subtract the small amount of specific dexamethasone binding
seen in COS-1 cells (a few percent or less of that seen in transfected
cells).
 |
ACKNOWLEDGMENTS
|
---|
The authors would like to acknowledge the assistance of the DNA
sequencing core and the tissue culture core of the University of
Colorado Cancer Center, and the Instrumentation Resource Facility at
the University of South Carolina School of Medicine.
 |
FOOTNOTES
|
---|
Address requests for reprints to: Paul R. Housley, Department of Pharmacology and Physiology, University of South Carolina School of Medicine, Columbia, South Carolina 29208. E-mail:
Housley{at}dcsmserver.med.sc.edu; or Steven K. Nordeen, Department of
This work has been supported by NIH Grants DK-37061 and DK-47951 to
S.K.N. and to P.R.H., respectively.
1 In the naming system that will be followed for
all remaining GFP-tagged receptor chimeras, the first letter designates
the origin of the receptor sequences comprising the Nterminal
domain through the hinge. The slash denotes the hinge-LBD border. The
source of each segment of the LBD is indicated by P or G. For receptors
with chimeric LBDs, subscripts denote the helices or other sequence
features encompassed by the PR segments in the chimeric LBD. The
GR-derived segments can be inferred. In all cases GFP is present at the
N terminus of the protein. See schematics of each receptor chimera in
the figures for exact boundaries of the junctions and other
details. 
Received for publication July 7, 2000.
Revision received October 3, 2000.
Accepted for publication October 9, 2000.
 |
REFERENCES
|
---|
-
Graham JD, Clarke CL 1997 Physiological action of
progesterone in target tissues. Endocr Rev 18:502519[Abstract/Free Full Text]
-
Porterfield SP 1997 Endocrine Physiology. Mosby-Year Book,
Inc., St. Louis, MO,, pp 139146
-
Evans RM 1988 The steroid and thyroid hormone receptor
superfamily. Science 240:889895[Medline]
-
Lieberman BA, Bona BJ, Edwards DP, Nordeen SK 1993 The
constitution of a progesterone response element. Mol Endocrinol 7:515527[Abstract]
-
Pratt WB, Toft DO 1997 Steroid receptor interactions with
heat shock protein and immunophilin chaperones. Endocr Rev 18:306360[Abstract/Free Full Text]
-
Ham J, Thomson A, Needham M, Webb P, Parker M 1988 Characterization of response elements for androgens, glucocorticoids
and progestins in mouse mammary tumour virus. Nucleic Acids Res 16:52635276[Abstract]
-
Strahle U, Boshart M, Klock G, Stewart F, Schutz G 1989 Glucocorticoid- and progesterone-specific effects are determined by
differential expression of the respective hormone receptors. Nature 339:629632[CrossRef][Medline]
-
Lambert JR, Nordeen SK 1998 Steroid-selective initiation of
chromatin remodeling and transcriptional activation of the mouse
mammary tumor virus promoter is controlled by the site of promoter
integration. J Biol Chem 273:3270832714[Abstract/Free Full Text]
-
Fuxe K, Wikstrom AC, Okret S, Agnati LF, Harfstrand A, Yu ZY,
Granholm L, Zoli M, Vale W, Gustafsson JA 1985 Mapping of
glucocorticoid receptor immunoreactive neurons in the rat tel- and
diencephalon using a monoclonal antibody against rat liver
glucocorticoid receptor. Endocrinology 117:18031812[Abstract]
-
Wikstrom AC, Bakke O, Okret S, Bronnegard M, Gustafsson JA 1987 Intracellular localization of the glucocorticoid receptor:
evidence for cytoplasmic and nuclear localization. Endocrinology 120:12321242[Abstract]
-
Rossini GP, Malaguti C 1994 Nanomolar concentrations of
untransformed glucocorticoid receptor in nuclei of intact cells. J
Steroid Biochem Mol Biol 51:291298[CrossRef][Medline]
-
Akner G, Wikstrom AC, Gustafsson JA 1995 Subcellular
distribution of the glucocorticoid receptor and evidence for its
association with microtubules. J Steroid Biochem Mol Biol 52:116[CrossRef][Medline]
-
Perrot-Applanat M, Logeat F, Groyer-Picard MT, Milgrom E 1985 Immunocytochemical study of mammalian progesterone receptor using
monoclonal antibodies. Endocrinology 116:14731484[Abstract]
-
Ylikomi T, Bocquel MT, Berry M, Gronemeyer H, Chambon P 1992 Cooperation of proto-signals for nuclear accumulation of estrogen and
progesterone receptors. EMBO J 11:36813694[Abstract]
-
Picard D, Yamamoto KR 1987 Two signals mediate
hormone-dependent nuclear localization of the glucocorticoid receptor.
EMBO J 6:33333340[Abstract]
-
Tang Y, Ramakrishnan C, Thomas J, DeFranco DB 1997 A role for
HDJ-2/HSDJ in correcting subnuclear trafficking, transactivation, and
transrepression defects of a glucocorticoid receptor zinc finger
mutant. Mol Biol Cell 8:795809[Abstract]
-
Guiochon-Mantel A, Loosfelt H, Lescop P, Sar S, Atger M,
Perrot-Applanat M, Milgrom E 1989 Mechanisms of nuclear localization of
the progesterone receptor: evidence for interaction between monomers.
Cell 57:11471154[Medline]
-
Cadepond F, Gasc JM, Delahaye F, Jibard N, Schweizer-Groyer G,
Segard-Maurel I, Evans R, Baulieu EE 1992 Hormonal regulation of the
nuclear localization signals of the human glucocorticosteroid receptor.
Exp Cell Res 201:99108[Medline]
-
Godowski PJ, Rusconi S, Miesfeld R, Yamamoto KR 1987 Glucocorticoid receptor mutants that are constitutive activators of
transcriptional enhancement [published erratum appears in Nature 1987
Mar 511;326(6108):105]. Nature 325:365368[CrossRef][Medline]
-
Hollenberg SM, Giguere V, Segui P, Evans RM 1987 Colocalization of DNA-binding and transcriptional activation functions
in the human glucocorticoid receptor. Cell 49:3946[Medline]
-
Danielsen M, Northrop JP, Jonklaas J, Ringold GM 1987 Domains
of the glucocorticoid receptor involved in specific and nonspecific
deoxyribonucleic acid binding, hormone activation, and transcriptional
enhancement. Mol Endocrinol 1:816822[Abstract]
-
Picard D, Salser SJ, Yamamoto KR 1988 A movable and
regulable inactivation function within the steroid binding domain of
the glucocorticoid receptor. Cell 54:10731080[Medline]
-
Urda LA, Yen PM, Simons Jr SS, Harmon JM 1989 Region-specific
antiglucocorticoid receptor antibodies selectively recognize the
activated form of the ligand-occupied receptor and inhibit the binding
of activated complexes to deoxyribonucleic acid. Mol Endocrinol 3:251260[Abstract]
-
Scherrer LC, Picard D, Massa E, Harmon JM, Simons Jr SS,
Yamamoto KR, Pratt WB 1993 Evidence that the hormone binding domain of
steroid receptors confers hormonal control on chimeric proteins by
determining their hormone-regulated binding to heat-shock protein 90.
Biochemistry 32:53815386[Medline]
-
Hache RJG, Tse R, Reich T, Savory JGA, Lefebvre YA 1999 Nucleocytoplasmic trafficking of steroid-free glucocorticoid receptor.
J Biol Chem 274:14321439[Abstract/Free Full Text]
-
Savory JGA, Hsu B, Laquian IR, Giffin W, Reich T, Hache RJG,
Lefebvre YA 1999 Discrimination between NL1- and NL2-mediated nuclear
localization of the glucocorticoid receptor. Mol Cell Biol 19:10251037[Abstract/Free Full Text]
-
Tsien RY 1998 The green fluorescent protein. Annu Rev Biochem 67:509544[CrossRef][Medline]
-
Htun H, Barsony J, Renyi I, Gould DL, Hager GL 1996 Visualization of glucocorticoid receptor translocation and intranuclear
organization in living cells with a green fluorescent protein chimera.
Proc Natl Acad Sci USA 93:48454850[Abstract/Free Full Text]
-
Zhu XG, Hanover JA, Hager GL, Cheng SY 1998 Hormone-induced
translocation of thyroid hormone receptors in living cells visualized
using a receptor green fluorescent protein chimera. J Biol Chem 273:2705827063[Abstract/Free Full Text]
-
Day RN, Nordeen SK, Wan Y 1999 Visualizing protein-protein
interactions in the nucleus of the living cells. Mol Endocrinol 13:517526[Free Full Text]
-
Lim CS, Baumann CT, Htun H, Xian W, Irie M, Smith CL, Hager GL 1999 Differential localization and activity of the A- and B-forms of
the human progesterone receptor using green fluorescent protein
chimeras. Mol Endocrinol 13:366375[Abstract/Free Full Text]
-
Williams SP, Sigler PB 1998 Atomic structure of progesterone
complexed with its receptor. Nature 393:392396[CrossRef][Medline]
-
Tanenbaum DM, Wang Y, Williams SP, Sigler PB 1998 Crystallographic comparison of the estrogen and progesterone
receptors ligand binding domains. Proc Natl Acad Sci USA 95:59986003[Abstract/Free Full Text]
-
Housley PR, Forsthoefel AM 1989 Isolation and characterization
of a mouse L cell variant deficient in glucocorticoid receptors.
Biochem Biophys Res Commun 164:480487[Medline]
-
Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer
H, Chambon P 1990 Two distinct estrogen-regulated promoters generate
transcripts encoding the two functionally different human progesterone
receptor forms A and B. EMBO J 9:16031614[Abstract]
-
Robin-Jagerschmidt C, Wurtz JM, Guillot B, Gofflo D, Benhamou
B, Vergezac A, Ossart C, Moras D, Philibert D 2000 Residues in the
ligand binding domain that confer progestin or glucocorticoid
specificity and modulate the receptor transactivation capacity. Mol
Endocrinol 14:10281037[Abstract/Free Full Text]
-
Tyagi RK, Amazit L, Lescop P, Milgrom E, Guiochon-Mantel A 1998 Mechanisms of progesterone receptor export from nuclei: role of
nuclear localization signal, nuclear export signal, and ran guanosine
triphosphate. Mol Endocrinol 12:16841695[Abstract/Free Full Text]
-
Liu J, DeFranco DB 1999 Chromatin recycling of glucocorticoid
receptors: implications for multiple roles of heat shock protein 90.
Mol Endocrinol 13:355365[Abstract/Free Full Text]
-
Liu J, DeFranco DB 2000 Protracted nuclear export of
glucocorticoid receptor limits its turnover and does not require the
exportin 1/CRM1-directed nuclear export pathway. Mol Endocrinol 14:4051[Abstract/Free Full Text]
-
King WJ, Greene GL 1984 Monoclonal antibodies localize
oestrogen receptor in the nuclei of target cells. Nature 307:745747[Medline]
-
Lombes M, Binart N, Delahaye F, Baulieu EE, Rafestin-Oblin ME 1994 Differential intracellular localization of human
mineralocorticosteroid receptor on binding of agonists and antagonists.
Biochem J 302:191197[Medline]
-
Robertson NM, Schulman G, Karnik S, Alnemri E, Litwack G 1993 Demonstration of nuclear translocation of the mineralocorticoid
receptor (MR) using an anti-MR antibody and confocal laser scanning
microscopy. Mol Endocrinol 7:12261239[Abstract]
-
Husmann DA, Wilson CM, McPhaul MJ, Tilley WD, Wilson JD 1990 Antipeptide antibodies to two distinct regions of the androgen receptor
localize the receptor protein to the nuclei of target cells in the rat
and human prostate. Endocrinology 126:23592368[Abstract]
-
Sar M, Lubahn DB, French FS, Wilson EM 1990 Immunohistochemical localization of the androgen receptor in rat and
human tissues. Endocrinology 127:31803186[Abstract]
-
Simental JA, Sar M, Lane MV, French FS, Wilson EM 1991 Transcriptional activation and nuclear targeting signals of the human
androgen receptor. J Biol Chem 266:510518[Abstract/Free Full Text]
-
Jenster G, Trapman J, Brinkmann AO 1993 Nuclear import of the
human androgen receptor. Biochem J 293:761768[Medline]
-
Tyagi RK, Lavrovsky Y, Ahn SC, Song CS, Chatterjee B, Roy AK 2000 Dynamics of intracellular movement and nucleocytoplasmic recycling
of the ligand-activated androgen receptor in living cells. Mol
Endocrinol 14:11621174[Abstract/Free Full Text]
-
Yang J, Liu J, DeFranco DB 1997 Subnuclear trafficking of
glucocorticoid receptors in vitro: chromatin recycling and
nuclear export. J Cell Biol 137:523538[Abstract/Free Full Text]
-
Dauvois S, White R, Parker MG 1993 The antiestrogen ICI 182780
disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 106:13771388[Abstract/Free Full Text]
-
Leslie KK, Kumar NS, Fox KE, Stephens J, A novel mechanism
underlying progestin resistance in endometrial cancer: loss of the
nuclear localization of progesterone B receptors. Keystone Symposium,
Nuclear Receptor 2000, Steamboat Springs, CO, 2000, p 105 (Abstract)
-
Boonyaratanakornkit V, Porter M, Anderson SA, Miller WT,
Edwards DP, Progesterone receptor contains a proline rich sequence in
the N domain that directly interacts with SH3 domains and activates
Src-tyrosine kinases. Keystone Symposium, Nuclear Receptor 2000,
Steamboat Springs, CO, 2000, p 96 (Abstract)
-
Giguere V, Hollenberg SM, Rosenfeld MG, Evans RM 1986 Functional domains of the human glucocorticoid receptor. Cell 46:645652[Medline]
-
Horton RM, Hunt HD, Ho SN, Pullen JK, Pease LR 1989 Engineering hybrid genes without the use of restriction enzymes: gene
splicing by overlap extension. Gene 77:6168[CrossRef][Medline]
-
Horton RM, Ho SN, Pullen JK, Hunt HD, Cai Z, Pease
LR 1993 Gene splicing by overlap extension. Methods Enzymol 217:270279[Medline]
-
Nordeen SK, Ogden CA, Taraseviciene L, Lieberman BA 1998 Extreme position dependence of a canonical hormone response element.
Mol Endocrinol 12:891898[Abstract/Free Full Text]